Asadulla Mohammed, MD
Pulmonary Disease · Berkley, MINPI 1508819350
Payments from drug & device makers
Across 978 payments — averaging $93.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$74K
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$2K
- Mylan Specialty L.p.$1K
- Inspire Medical Systems, Inc.$954
- plus $9K from 42 others
What the payments were for
- Speaking & faculty fees$69,90076%
- Travel & lodging$2,2122%
- Food & beverage$18,94721%
- Education$3260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$68,445
- OPSUMIT$64,340
- Inspire Upper Airway Stimulation System$849
- TEZSPIRE$218
- SMARTVEST$108
How this compares
$91,386 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $359,850 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 274 | $214,215 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $192,748 |
| OpsumitMacitentan | 12 | $154,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 151 | $119,981 |
| Dupixent SyringeDupilumab | 26 | $96,823 |
| Dupixent PenDupilumab | 25 | $93,639 |
| TezspireTezepelumab-Ekko | 21 | $89,517 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $74,923 |
| Spiriva RespimatTiotropium Bromide | 65 | $49,261 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $34,559 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $18,452 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 56 | $15,442 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $14,655 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,572 | $427,562127 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,881 | $270,899380 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $2,218 | $215,205199 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $538 | $192,74813 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $74,347 | $154,08612 claims |
| Grifols USA, LLCProlastin C | $744 | $74,92312 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $217 | $3,89513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Berkley
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
- Yvonne HuangAnn Arbor$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.